Literature DB >> 16473737

Rethinking TNM: breast cancer TNM classification for treatment decision-making and research.

Umberto Veronesi1, Giuseppe Viale, Nicole Rotmensz, Aron Goldhirsch.   

Abstract

Current classification for solid tumors is based upon characteristics of their extent. Size of the primary tumor, presence of metastatic regional lymph nodes and/or of distant metastases are the key elements for their categorization. Treatment decision-making may depend upon defined extent of disease, but it requires the knowledge of several other factors. Furthermore, effective therapeutics is less dependent upon extent of disease, biological features being increasingly instrumental for treatment choice. A new classification that integrates both requisites is proposed. The scope of this proposal is to transform the current rigid and gross categorization into a more analytical and fine tuned listing including biological variables, making staging allocation more flexible and functional for proper clinical and research needs in the present and for the future. The significant changes we propose are:

Entities:  

Mesh:

Year:  2006        PMID: 16473737     DOI: 10.1016/j.breast.2005.11.011

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  21 in total

1.  Challenges in ductal carcinoma in situ risk communication and decision-making: report from an American Cancer Society and National Cancer Institute workshop.

Authors:  Ann H Partridge; Joann G Elmore; Debbie Saslow; Worta McCaskill-Stevens; Stuart J Schnitt
Journal:  CA Cancer J Clin       Date:  2012-04-04       Impact factor: 508.702

2.  The TNM classification of breast cancer: need for change.

Authors:  Paolo Arnone; Stefano Zurrida; Giuseppe Viale; Silvia Dellapasqua; Emilia Montagna; Paola Arnaboldi; Mattia Intra; Umberto Veronesi
Journal:  Updates Surg       Date:  2010-10

3.  Decreased expression of the CHD5 gene and its clinicopathological significance in breast cancer: Correlation with aberrant DNA methylation.

Authors:  Zhongliang Ma; Jinlian Song; Simin Liu; Linlin Han; Yangping Chen; Yaqiu Wang; Chundong Yu; Lin Hou
Journal:  Oncol Lett       Date:  2016-09-16       Impact factor: 2.967

Review 4.  Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way.

Authors:  Nuket Eliyatkın; Evrim Yalçın; Baha Zengel; Safiye Aktaş; Enver Vardar
Journal:  J Breast Health       Date:  2015-04-01

5.  Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System.

Authors:  Mariana Chavez-MacGregor; Elizabeth A Mittendorf; Christina A Clarke; Daphne Y Lichtensztajn; Kelly K Hunt; Sharon H Giordano
Journal:  Oncologist       Date:  2017-06-07

6.  ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma.

Authors:  Gerusa G Seniski; Anamaria A Camargo; Daniela F Ierardi; Edneia A S Ramos; Mariana Grochoski; Enilze S F Ribeiro; Iglenir J Cavalli; Fabio O Pedrosa; Emanuel M de Souza; Silvio M Zanata; Fabrício F Costa; Giseli Klassen
Journal:  BMC Cancer       Date:  2009-03-06       Impact factor: 4.430

Review 7.  Lobular and ductal intraepithelial neoplasia.

Authors:  F A Tavassoli
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

8.  T1a triple negative breast cancer has the worst prognosis among all the small tumor (<1 cm) of TNBC and HER2-rich subtypes.

Authors:  Changjun Wang; Ziyuan Chen; Yidong Zhou; Wei Huang; Hanjiang Zhu; Feng Mao; Yan Lin; Yanna Zhang; Jinghong Guan; Xi Cao; Qiang Sun
Journal:  Gland Surg       Date:  2021-03

9.  The Will Rogers phenomenon, breast cancer and race.

Authors:  Mary R Nittala; Eswar K Mundra; S Packianathan; Divyang Mehta; Maria L Smith; William C Woods; Shawn McKinney; Barbara S Craft; Srinivasan Vijayakumar
Journal:  BMC Cancer       Date:  2021-05-17       Impact factor: 4.430

10.  Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer.

Authors:  Edneia A S Ramos; Anamaria A Camargo; Karin Braun; Renata Slowik; Iglenir J Cavalli; Enilze M S F Ribeiro; Fábio de O Pedrosa; Emanuel M de Souza; Fabrício F Costa; Giseli Klassen
Journal:  BMC Cancer       Date:  2010-01-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.